EGFR and pachyonychia congenita: Ultimately, OTUD7B mediates EGFR deubiquitination and stability and MAPK signaling pathway activation, suggesting that linc00976/miR-137/OTUD7B/EGFR axis may act as a feasible therapeutic target for PC.